Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gritstone bio, Inc. - Common Stock (NQ:GRTS)

0.0322 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gritstone bio, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Why Gritstone bio Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Gainers Inpixon (NASDAQ: INPX) shares rose 44.6% to $0.2023 in pre-market trading after gaining around 10% on Wednesday. 
Via Benzinga
Why Is Vaccine Focused Gritstone bio Stock Trading Higher Today?
Gritstone Bio Inc (NASDAQ: GRTS) received a contract from the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase 2b comparative study evaluating its self-amplifying mRNA... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're checking out the biggest pre-market stock movers worth watching on Friday with a dive into all of the latest market stories! 
Via InvestorPlace
Gritstone Bio: Q1 Earnings Insights
 
Via Benzinga
Gritstone Oncology's Return On Capital Employed Overview
 
Via Benzinga
Earnings Outlook For Gritstone Oncology
 
Via Benzinga
Gritstone bio Shares Jump After Updated Overall Survival Data From Colorectal Cancer Candidate
 
Via Benzinga
Gritstone's Cancer Drug Shows Strong Tumor-Specific Responses In Various Settings
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle
Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'... 
Via Benzinga
Moderna, Merck's Cancer Vaccines Exhibit Positive Outcomes Under Midstage Trial
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
Startling cancer vaccine results from Moderna may point to the next big thing in biotech. 
Via Investor's Business Daily
Why Planet Labs Shares Are Trading Higher; Here Are 28 Stocks Moving Premarket
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares rose 74.7% to $0.4104 in pre-market trading after declining 4% on Wednesday. 
Via Benzinga
Why G Medical Innovations Shares Are Trading Lower By 35%; Here Are 25 Stocks Moving Premarket
Gainers EUDA Health Holdings Limited (NASDAQ: EUDA) shares rose 88.1% to $8.40 in pre-market trading after merger completed with 8i Acquisition SPAC last week. 
Via Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning! 
Via InvestorPlace
Block To 100? Plus This Analyst Slashes PT On Estée Lauder By 32%
  Barclays slashed the price target on Block, Inc. (NYSE: SQ) from $130 to $100. Block shares rose 1% to $60.70 in pre-market trading. 
Via Benzinga
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Gritstone Oncology's Return On Capital Employed Overview
Benzinga Pro data, Gritstone Oncology (NASDAQ:GRTS) reported Q2 sales of $5.47 million. Earnings fell to a loss of $29.52 million, resulting in a 2.07% decrease from last quarter. 
Via Benzinga
Goldman Sachs Is Bearish On Gritstone Bio: 'Avenues For Financing Are Likely Too Modest'
Gritstone bio Inc (NASDAQ: GRTS) has insufficient cash either to reach de-risking catalysts for its lead oncology program, GRANITE, or to support the clinical development of its second program, SLATE,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Earnings Outlook For Gritstone Oncology
Gritstone Oncology (NASDAQ:GRTS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Gritstone Bio's Earnings Outlook
Gritstone Bio (NASDAQ:GRTS) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Gritstone Bio... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.